NasdaqGM - Delayed Quote • USD
Phibro Animal Health Corporation (PAHC)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 4:20 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 4 | 4 |
Avg. Estimate | 0.29 | 0.35 | 1.1 | 1.23 |
Low Estimate | 0.29 | 0.33 | 1.09 | 1.12 |
High Estimate | 0.29 | 0.37 | 1.13 | 1.39 |
Year Ago EPS | 0.29 | 0.38 | 1.21 | 1.1 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 4 | 4 |
Avg. Estimate | 254.82M | 265.53M | 999.04M | 1.03B |
Low Estimate | 253.65M | 265.07M | 995M | 1.01B |
High Estimate | 256M | 266M | 1B | 1.04B |
Year Ago Sales | -- | 255M | 977.9M | 999.04M |
Sales Growth (year/est) | -- | 4.10% | 2.20% | 3.20% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.33 | 0.38 | 0.23 | 0.28 |
EPS Actual | 0.29 | 0.38 | 0.14 | 0.33 |
Difference | -0.04 | 0 | -0.09 | 0.05 |
Surprise % | -12.10% | 0.00% | -39.10% | 17.90% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.29 | 0.35 | 1.1 | 1.23 |
7 Days Ago | 0.29 | 0.35 | 1.1 | 1.23 |
30 Days Ago | 0.29 | 0.35 | 1.1 | 1.23 |
60 Days Ago | 0.29 | 0.35 | 1.11 | 1.24 |
90 Days Ago | 0.3 | 0.36 | 1.07 | 1.21 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | PAHC | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 0.00% | -- | -- | 0.40% |
Next Qtr. | -7.90% | -- | -- | 9.90% |
Current Year | -9.10% | -- | -- | 4.30% |
Next Year | 11.80% | -- | -- | 13.40% |
Next 5 Years (per annum) | 2.40% | -- | -- | 11.09% |
Past 5 Years (per annum) | -4.12% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
Earnings
Upgrades & Downgrades
Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 11/9/2023 |
Reiterates | Roth MKM: Buy to Buy | 9/1/2023 |
Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 8/31/2023 |
Reiterates | Roth MKM: Buy to Buy | 8/29/2023 |
Reiterates | Morgan Stanley: Equal-Weight to Equal-Weight | 7/27/2023 |
Maintains | Morgan Stanley: Equal-Weight | 5/4/2023 |
Related Tickers
AGXRW Agile Therapeutics, Inc.
0.0001
0.00%
LOWLF Lowell Farms Inc.
0.0850
+1.19%
TKNO Alpha Teknova, Inc.
1.7990
-10.05%
ORGO Organogenesis Holdings Inc.
2.9800
+0.34%
INDV Indivior PLC
18.63
+0.49%
SSIC Silver Spike Investment Corp.
11.11
+0.27%
PBH Prestige Consumer Healthcare Inc.
71.22
+2.03%
KHRNF Khiron Life Sciences Corp.
0.0000
0.00%
TLLTF TILT Holdings Inc.
0.0295
+1.72%
LFCR Lifecore Biomedical, Inc.
6.45
+2.54%